2023
Ocular complications of plasma cell dyscrasias
Singh R, Singhal S, Sinha S, Cho J, Nguyen A, Dhingra L, Kaur S, Sharma V, Agarwal A. Ocular complications of plasma cell dyscrasias. European Journal Of Ophthalmology 2023, 33: 1786-1800. PMID: 36760117, PMCID: PMC10472748, DOI: 10.1177/11206721231155974.Peer-Reviewed Original ResearchConceptsPlasma cell dyscrasiaMonoclonal gammopathyMultiple myelomaMalignant plasma cellsEfficacious treatment strategiesSearch of PubMedOcular presentationOcular complicationsTreating ophthalmologistClinical suspicionAsymptomatic patientsOphthalmological signsWaldenstrom's macroglobulinemiaSystemic findingsOphthalmologic disordersPre-malignantUnderlying diseasePosterior segmentPlasma cellsSkin changesTreatment strategiesOver-secretionEarly diagnosisCochrane DatabaseSystemic amyloidosis
2020
Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients
Girgis S, Lin S, Pillarisetti K, Banerjee A, Goldberg J, Shetty S, Stephenson T, Hilder B, Hanna B, Smit J, Adams H, Sun Y, Infante J, Elsayed Y, Sharma A. Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients. Blood 2020, 136: 35. DOI: 10.1182/blood-2020-140565.Peer-Reviewed Original ResearchMinimal anticipated biological effect levelCurrent equity holderEx vivo cytotoxicity assaysPhase 2 doseMM patientsBone marrow samplesTherapeutic rangeFIH studiesMultiple myelomaMarrow samplesMM cellsClinical dataCytotoxicity assayRecommended phase 2 doseRelapsed refractory MM patientsB-cell maturation antigenClinical starting doseExpression of BCMALow dose cohortRefractory MM patientsHigh tumor burdenPatient bone marrow samplesEx vivo cytotoxicityMalignant plasma cellsImmuno-oncology drugs
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply